IFNA2 and measles: In other studies, patients who frequently suffered from respiratory tract infections, leading to exacerbations of chronic illnesses, received either bacterial lysate (I.R.S. 19) or recombinant interferon alpha-2b (Viferon®) as medication support for 14 days after booster vaccination against measles and mumps.